Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.
Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.
At present, our main expression system is fusion and tandem copy method expression ,polypeptides with other special functions enzyme expressed syncretic by repeated tandem expression, so that the product has a high expression level and avoids the toxicity caused by chemical synthesis.
Our unique and independent expression system established by our R&D team has been successful tested under the condition of 150L scale,it proves a high-density fermentation process can be industrially Large-scale applicated.The protease produced by self-expression can obtain more than 95% enzyme digestion efficiency, propeptide treatment, intermediate peptide purification, fat chain modification, fine purification and raw material preparation process.
The purity of the raw material dry powder is not less than 99%. The HPLC retention time and mass spectrometry molecular weight of the drug substance developed by us are completely consistent with the Novo Nordisk Victoza.
Third part lab tested The cell viability in vitro and PK & PD determination in monkeys, the pharmacokinetics,EC50 and glucagon control effect are consistent with the Novo Nordisk Victoza
according to 18mg: 3.0ml injection, one kilogram of raw materials can produce 50,000 injections .